| Item type |
共通アイテムタイプ / Common item types(1) |
| 公開日 |
2025-10-22 |
| タイトル |
|
|
タイトル |
Prognostic outcomes in patients with metastatic renal cell carcinoma receiving second-line treatment with tyrosine kinase inhibitor following first-line immune-oncology combination therapy |
| 言語 |
|
|
言語 |
eng |
| キーワード |
|
|
主題 |
first-line IO combination therapy |
| キーワード |
|
|
主題 |
second-line TKI |
| キーワード |
|
|
主題 |
PFS |
| キーワード |
|
|
主題 |
risk classification |
| その他のタイトル |
|
|
その他のタイトル |
Second-line TKI following IO combination |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| アクセス権 |
|
|
アクセス権 |
open access |
|
アクセス権URI |
http://purl.org/coar/access_right/c_abf2 |
| 著者 |
Matsushita, Yuto
Kojima, Takahiro
Osawa, Takahiro
Sazuka, Tomokazu
Hatakeyama, Shingo
Goto, Keisuke
Numakura, Kazuyuki
Yamana, Kazutoshi
Kandori, Shuya
Fujita, Kazutoshi
Ueda, Kosuke
Tanaka, Hajime
Tomida, Ryotaro
Kurahashi, Toshifumi
Bando, Yukari
Nishiyama, Naotaka
Kimura, Takahiro
Yamashita, Shimpei
Kitamura, Hiroshi
Miyake, Hideaki
|
| 著者情報 |
松下, 雄登
|
| 書誌情報 |
en : International Journal of Urology
巻 31,
号 5,
p. 526-533,
発行日 2024-05-04
|
| 出版者 |
|
|
出版者 |
John Wiley and Sons |
| 出版者 |
|
|
出版者 |
日本泌尿器学会 = The Japanese Urological Association |
| 権利 |
|
|
権利情報 |
This is the peer reviewed version of the following article: "Prognostic outcomes in patients with metastatic renal cell carcinoma receiving second-line treatment with tyrosine kinase inhibitor following first-line immune-oncology combination therapy"; 31(5), pp526-533, c2024, which has been published in final form at https://doi.org/10.1111/iju.15396. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. This article may not be enhanced, enriched or otherwise transformed into a derivative work, without express permission from Wiley or by statutory rights under applicable legislation. Copyright notices must not be removed, obscured or modified. The article must be linked to Wiley’s version of record on Wiley Online Library and any embedding, framing or otherwise making available the article or pages thereof by third parties from platforms, services and websites other than Wiley Online Library must be prohibited. |
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Objectives: This study aimed to assess the prognostic outcomes in mRCC patients receiving second-line TKI following first-line IO combination therapy.
Methods: This study retrospectively included 243 mRCC patients receiving second-line TKI after first-line IO combination therapy: nivolumab plus ipilimumab (n=189, IO-IO group) and either pembrolizumab plus axitinib or avelumab plus axitinib (n=54, IO-TKI group). Oncological outcomes between the 2 groups were compared, and prognostication systems were developed for these patients.
Results: In the IO-IO and IO-TKI groups, the objective response rates to second-line TKI were 34.4% and 25.9% (P=0.26), the median PFS periods were 9.7 and 7.1 months (P=0.79), and the median OS periods after the introduction of second-line TKI were 23.1 and 33.5 months (P=0.93), respectively. Among the several factors examined, non-CCRCC, high CRP and low albumin levels were identified as independent predictors of both poor PFS and OS by multivariate analyses. It was possible to precisely classify the patients into 3 risk groups regarding both PFS and OS according to the positive numbers of the independent prognostic factors. Furthermore, the c-indices of this study were superior to those of previous systems as follows: 0.75, 0.64, and 0.61 for PFS prediction and 0.76, 0.70, and 0.65 for OS prediction by the present, IMDC and MSKCC systems, respectively.
Conclusions: There were no significant differences in the prognostic outcomes after introducing second-line TKI between the IO-IO and IO-TKI groups, and the histopathology, CRP and albumin levels had independent impacts on the prognosis in mRCC patients receiving second-line TKI, irrespective of first-line IO combination therapies. |
| PISSN |
|
|
収録物識別子 |
0919-8172 |
| EISSN |
|
|
収録物識別子 |
1442-2042 |
| NII書誌ID (NCID) |
|
|
収録物識別子 |
AA11042471 |
| PubMed番号 (PMID) |
|
|
|
関連識別子 |
38240169 |
| 医中誌論文ID (ICHUSHI) |
|
|
|
関連識別子 |
2025190693 |
| 出版社DOI |
|
|
|
関連識別子 |
https://doi.org/10.1111/iju.15396 |
| 出版タイプ |
|
|
出版タイプ |
AM |
|
出版タイプResource |
http://purl.org/coar/version/c_ab4af688f83e57aa |
IJU-31-526.pdf (1 MB)
